The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma

Vidac Pharma: Attacking the Warburg effect

To understand why Vidac Pharma could be so attractive to companies like Eli Lilly or BioNTech, one must look deep into cell biology. Most cancer drugs attack the cell's DNA or use the immune system. Vidac takes a different approach and targets the so-called Warburg effect. Cancer cells have a fundamentally different metabolism than healthy cells. They burn sugar in turbo mode, even when there is enough oxygen available. Vidac has developed molecules that switch off this cancer turbo.

At the heart of the pipeline is the drug candidate VDA-1275. As current data show, this molecule not only acts directly against tumor cells, but also triggers an immunological chain reaction. In preclinical studies, the combination of VDA-1275 with established chemotherapies led to a synergistic effect that significantly increased survival rates. Particularly exciting: Vidac recently obtained a patent in the US that protects this mechanism of action well into the 2030s. This gives the Company a monopoly on an entirely new therapeutic target.

Connectivity: Who needs Vidac?

The question now is: Who are the potential partners? With its entry into Seamless Therapeutics in Dresden, Eli Lilly has shown that it is willing to take early-stage risks if the technological platform is right. The Dresden-based startup's technology targets hearing loss, but could also be used in other areas. As Lilly is expanding massively into oncology and seeking diversification beyond diabetes, Vidac's metabolic approach would be a perfect complement that does not compete internally with existing products.

However, a partnership with BioNTech could be even more obvious. With its billions in profits from the COVID era, the Mainz-based company is currently transforming itself into a global cancer specialist. BioNTech focuses heavily on immunotherapies such as CAR-T or mRNA, but these therapies often fail due to the hostile environment in the tumor, known as the tumor microenvironment. This is precisely where Vidac could open doors: by normalizing the tumor's metabolism, VDA-1275 makes cancer cells vulnerable to the immune system again. This synergy would be extremely elegant from a scientific perspective and highly attractive from a commercial standpoint.

The validation factor

A decisive argument for investors is the external validation that Vidac has already received. The analysis firm Sphene Capital recently renewed its "Buy" recommendation after Vidac received approval for a Phase 2 study in Germany. The fact that a small biotech company has cleared the strict hurdles set by the German regulatory authorities is considered a seal of quality in the industry.

In addition, clinical data from Vidac's ointment for actinic keratosis (a precursor to skin cancer) show that the platform works in humans and is safe. This "proof of concept" significantly reduces the technological risk, as it proves that interfering with cell metabolism has no toxic side effects on healthy organs.

Vidac shares as a speculative addition

For investors, the situation at Vidac Pharma is extremely exciting: its market capitalization is extremely low compared to the billion-dollar valuations of potential partners such as BioNTech or Eli Lilly. The market currently appears to be primarily pricing in the dermatological projects, but largely ignoring the blockbuster potential of systemic cancer drugs.

Of course, as a company in clinical development, Vidac Pharma is not for conservative investors, as the risk of setbacks in studies is always present in the biotech sector. However, for speculative investors, the stock offers a rare opportunity: entry into a validated technology platform shortly before the major Phase 2 efficacy data is available. If this data is positive, Vidac is likely to quickly become the focus of large corporations looking for precisely such innovative puzzle pieces for their pipelines. With its well-founded technology that is compatible with other approaches, Vidac is predestined to become the next junior partner of the pharmaceutical giants, generating headlines and share price gains.